Jounce Therapeutics (JNCE) is Initiated by JP Morgan to “Overweight”

Jounce Therapeutics (JNCE) was Initiated by JP Morgan to “Overweight” and the brokerage firm has set the Price Target at $28. JP Morgan advised their Clients and Investors in a research report released on Feb 21, 2017.

Based on several research reports , JP Morgan Initiated Jounce Therapeutics on Feb 21, 2017 to “Overweight”, Price Target of the shares are set at $28.Jounce Therapeutics was Initiated by Wells Fargo to “Outperform” on Feb 21, 2017.

Jounce Therapeutics

Add Comment